Actively Recruiting
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
Led by Beijing Tsinghua Chang Gung Hospital · Updated on 2026-04-20
108
Participants Needed
1
Research Sites
5 weeks
Total Duration
On this page
Sponsors
B
Beijing Tsinghua Chang Gung Hospital
Lead Sponsor
A
Affiliated Hospital of Hebei University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The precise treatment of primary hepatocellular carcinoma (HCC) highly depends on accurate disease staging (CNLC, TNM, BCLC) and scientific treatment decision-making, which necessitate the integration of both imaging and clinical baseline data. This study prospectively recruits HCC patients and clinical physicians across different hospital tiers to evaluate the clinical value of a self-developed artificial intelligence (AI) model in assisting multi-dimensional comprehensive assessment and treatment decision-making. Utilizing a Multi-Rater Multi-Case (MRMC) crossover balanced design, the study compares the accuracy of clinical evaluations performed by physicians under "unassisted (without AI)" versus "AI-assisted" conditions. A key focus is to explore whether AI can significantly enhance the comprehensive assessment capabilities of physicians in primary/secondary care hospitals, thereby prospectively reducing diagnostic and therapeutic heterogeneity across different institutional levels.
CONDITIONS
Official Title
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Suspected or newly diagnosed primary hepatocellular carcinoma (HCC) confirmed by pathology or meeting China Liver Cancer (CNLC) guidelines
- Complete baseline clinical data including history, ECOG PS score, liver function, coagulation, tumor markers such as AFP, and baseline abdominal contrast-enhanced CT
- Written informed consent provided for use of clinical data in this trial
You will not qualify if you...
- Secondary (metastatic) liver cancer or severe malignancies of other systems
- Incomplete baseline imaging or laboratory tests preventing accurate staging calculations
- Prior anti-tumor therapies for liver cancer before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tsinghua Changgung Hospital
Beijing, Changping, China, 102218
Actively Recruiting
Research Team
J
Jitao Wang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here